Mileshkin L, et al. - In this phase 2 trial, researchers assessed the clinical benefit rate as well as the impact on quality of life (QOL) of anastrozole given to treat patients with endometrial cancer. Patients with ER and/or PR positive metastatic endometrial cancer not previously treated with hormonal therap, were administered anastrozole 1 mg/d. With anastrozole, a clinical benefit rate of 44% was observed in these patients, despite a relatively low objective response rate. Patients tolerated anastrozole well and the observed RECIST partial response rate was 7%. The median duration of clinical benefit was 5.6 months. Clinically significant improvements in QOL were evident in relation to clinical benefit.